Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype

BMC Cancer

Table 1 Correlation between CD10 expression and clinicopathological parameters in breast cancer

Clinicopathological parameters	Total	CD10 expression in stromal cells		CD10 expression in tumoral cells
Clinicopathological parameters	Total	n (%)	p-value*	n (%)	p-value*
Age
< 35 years	18	4 (22.2)	0.33	1 (5.5)	0.87
35–50 years	63	9 (14.2)		5 (7.9)
> 50 years	52	13 (25)		3 (5.7)
Menopausal status
Pre-	70	15 (21.4)	0.56	6 (8.5)	0.49
Post-	63	11 (17.4)		3 (4.7)
Familial history
Positive	10	3 (30)	0.11	1 (10)	0.37
Negative	102	11 (10.7)		4 (3.9)
Histological grade^a
Grade I	26	0 (0)	0.01	0 (0)	0.03
Grade II	56	12 (21,4)		1 (1.7)
Grade III	51	14 (27.4)		8 (1.5)
Tumor size
≤ 20 mm	43	6 (13.9)	0.26	2 (4.6)	0.5
> 20 mm	90	20 (2)		7 (7.7)
Lymph node metastasis^b
No metastasis	46	9 (19.5)	0.01	3 (6.5)	0.9
1 to 3 lymph nodes	37	3 (8.1)		3 (8.1)
> 3 lymph nodes	20	8 (40)		1 (5)
Visceral metastases
Positive	10	0 (0)	0.35	0 (0)	1
Negative	78	14 (17.9)		5 (6.4)
Estrogen receptors^c
Positive	62	11 (17.7)	0.62	1 (1.6)	0.002
Negative	71	15 (21.1)		8 (11.2)
Progesterone receptors^c
Positive	65	10 (15.3)	0.23	1 (1.5)	0.001
Negative	68	16 (23.3)		8 (11.2)
HER2 status^d
Positive	32	8 (25)	0.37	3 (9.3)	0.5
Negative	101	18 (17.8)		6 (5.9)

^aScarff–Bloom and Richardson classification
^bThirty patients did not have lymph node resection
^cEstrogen and progesterone receptors status was evaluated by immunohistochemistry, and considered positive if ≥1% of tumor cells showed nuclear staining
^dEvaluated by immunohistochemistry and considered positive if scored 3+
*Bold number indicates significant p-value

ISSN: 1471-2407